- Home
- AORT vs ELVN Comparison
AORT vs ELVN Comparison
Compare AORT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- ELVN
- Stock Information
- Founded
- AORT 1984
- ELVN 2016
- Country
- AORT United States
- ELVN United States
- Employees
- AORT N/A
- ELVN N/A
- Industry
- AORT Medical/Dental Instruments
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- ELVN Health Care
- Exchange
- AORT Nasdaq
- ELVN Nasdaq
- Market Cap
- AORT 1.0B
- ELVN 927.8M
- IPO Year
- AORT 1993
- ELVN 2020
- Fundamental
- Price
- AORT $30.26
- ELVN $21.30
- Analyst Decision
- AORT Strong Buy
- ELVN Strong Buy
- Analyst Count
- AORT 6
- ELVN 5
- Target Price
- AORT $32.00
- ELVN $39.60
- AVG Volume (30 Days)
- AORT 305.7K
- ELVN 594.3K
- Earning Date
- AORT 08-07-2025
- ELVN 08-12-2025
- Dividend Yield
- AORT N/A
- ELVN N/A
- EPS Growth
- AORT N/A
- ELVN N/A
- EPS
- AORT N/A
- ELVN N/A
- Revenue
- AORT $390,084,000.00
- ELVN N/A
- Revenue This Year
- AORT $12.18
- ELVN N/A
- Revenue Next Year
- AORT $10.39
- ELVN N/A
- P/E Ratio
- AORT N/A
- ELVN N/A
- Revenue Growth
- AORT 5.94
- ELVN N/A
- 52 Week Low
- AORT $21.97
- ELVN $13.30
- 52 Week High
- AORT $32.33
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- AORT 65.93
- ELVN 55.53
- Support Level
- AORT $28.14
- ELVN $18.53
- Resistance Level
- AORT $29.59
- ELVN $24.11
- Average True Range (ATR)
- AORT 0.67
- ELVN 1.96
- MACD
- AORT -0.04
- ELVN 0.15
- Stochastic Oscillator
- AORT 88.33
- ELVN 55.68
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.